A 34-year-old Maryland biotechnology company that has never successfully launched a vaccine faces a world impatient for more coronavirus shots to quell a pandemic – but the wait isn’t over.
Novavax, bolstered by $1.6 billion in federal funding, is unlikely to seek emergency use authorization for its coronavirus vaccine in the United States until June at the earliest, according to four people who have recently been briefed on the company’s plans.
As supplies of three authorized coronavirus vaccines have increased in the United States, the role of the Novavax vaccine domestically remains unclear. But the company’s shots, shown to be about 90 percent effective in a 15,000-person United Kingdom
→ Continue reading at Boston - News